Search Results
Informed by the tumor: The power of a personalized ctDNA Assay for Treatment Monitoring in HER2
MRD detection rates with a personalized and a tumor-informed ctDNA assay in patients with stage ...
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Biomarkers: Next Generation Sequencing and Updates on NTRK and ctDNA
Dr. Nicholas Turner | What ctDNA Can Tell Us | SABCS 2022 | Educational Session
Emerging Role of Circulating Tumor DNA in the Management of Thoracic Malignancies (Sept. 26, 2024)
AllyCon 2021: How ctDNA is Used in Colorectal Cancer Recurrence Monitoring
HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
Diagnostic Testing Panel Discussion | 2022 Best of Breast Conference
AllyCon 2021: Personalized Treatment Options for Colorectal Cancer
Breast Cancer Signatera Webinar
May Cho, MD | ctDNA and MRD Testing with the Expanded Access Program
